



Five quinolizidine alkaloids with anti-tobacco mosaic virus activities from two species of *Sophora*

Ji Zhang^{a,b,c,1}, Tong Zhang^{a,b,c,1}, Qiao An^{a,b}, Peng Zhang^{a,b}, Cai-Yan Tian^{a,b,d}, Chun-Mao Yuan^{a,b}, Ping Yi^{a,b}, Zhan-Xing Hu^{a,b,*}, Xiao-Jiang Hao^{a,b,e,f,*}

^a State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China

^b Natural Products Research Center of Guizhou Province, Guiyang 550014, China

^c School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang 550025, China

^d School of Pharmacy, Guizhou University of Traditional Chinese Medicine, Guiyang 550025, China

^e State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Science, Kunming 650201, China

^f Research Unit of Chemical Biology of Natural Anti-Virus Products, Chinese Academy of Medical Sciences, Kunming 650201, China

ARTICLE INFO

Article history:

Received 24 June 2023

Revised 8 August 2023

Accepted 10 August 2023

Available online 12 August 2023

Keywords:

Matrine-type alkaloids

Aloperine-type alkaloids

Sophora tonkinensis

Sophora alopecuroides

Anti-tobacco mosaic virus

ABSTRACT

Three novel matrine-type alkaloids (**1–3**) and two unprecedented aloperine-type alkaloids (**4** and **5**) were isolated from the root of *Sophora tonkinensis* and the seeds of *Sophora alopecuroides* respectively. Notably, compound **1** possessed an unprecedented 6/5/6 tricyclic skeleton, while compounds **2** and **3** characterized by rare 6/6/5/6 tetracyclic system and 6/6/6/6/6 pentacyclic system respectively. Moreover, compound **4** possessed an unprecedented 6/7/6/6 tetracyclic core, and compound **5** characterized by rare 6/6/6/6 tetracyclic skeleton. Their structures were elucidated by comprehensive spectroscopic data analysis and electronic circular dichroism (ECD) calculations. Biological tests indicated that compound **5** displayed significant anti-tobacco mosaic virus (TMV) activity compared with the positive control ningnanmycin.

© 2024 Published by Elsevier B.V. on behalf of Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences.

Quinolizidine alkaloids (QAs) are characteristic natural products of many Fabaceae, especially abundant in the tribes *Genisteae*, *Sophoreae*, and *Thermopsidae* [1–5]. They are biosynthesized from L-lysine through the decarboxylated intermediate cadaverine, which undergoes a series of enzymatic reactions to form different types of QAs, such as matrine-type, aloperine-type, cytosine-type, anagrine-type, thermopsine-type, and sparteine-type [6–8]. QAs have been reported to have various biological activities including antibacterial, anti-inflammatory, antiviral, anti-allergic, and antitumor activities [9–17]. Previously, we found several new QAs with anti-plant virus activities from the seeds of *T. lanceolata* [18,19]. In our continuing efforts to discover novel, highly effective antiviral agents from QAs, the chemical components of the root of *S. tonkinensis* and the seeds of *S. alopecuroides* were carried out, which led to the isolation of three novel matrine-type alkaloids (**1–3**) and two unprecedented aloperine-type alkaloids (**4** and **5**) respectively. Notably, compounds **1–3** possessed unprecedented 6/5/6 tricyclic system, 6/6/5/6 tetracyclic skeleton, and 6/6/6/6/6

pentacyclic frame respectively. In addition, compound **4** possessed an unprecedented 6/7/6/6 tetracyclic skeleton, while compound **5** characterized by rare 6/6/6/6 tetracyclic skeleton (Fig. 1). The anti-tobacco mosaic virus (TMV) activities of isolates were screened using the half-leaf method. Herein, the isolation, structural determinations, and bioactivity assays were described.

Sophortonkine A (**1**) with the molecular formula of C₁₁H₁₂N₂O on the basis of the high resolution electrospray ionization mass spectroscopy (HRESIMS) (*m/z* 211.0846 [M + Na]⁺, calcd. for 211.0842). The nuclear magnetic resonance (NMR) data of **1** displayed a pyridine ring [δ_C 157.9, 149.6 (δ_H 8.54, d, *J* = 4.9 Hz), 134.2, 129.7 (δ_H 7.54, d, *J* = 7.7 Hz), 122.4 (δ_H 7.24, dd, *J* = 7.7, 4.9 Hz)] (Tables S1 and S2 in Supporting information). Moreover, the ¹H–¹H correlation spectroscopy (COSY) correlations of H-6/H₂-7/H₂-8/H₂-9, combined with the heteronuclear multiple bond correlation spectroscopy (HMBC) correlations from H₂-12 to C-5 (δ_C 134.2)/C-6 (δ_C 61.9)/C-10 (δ_C 169.0)/C-13 (δ_C 157.9), from H-9 to C-10, and from H-6 to C-5 indicated the existence of hexahydro-5(1*H*)-indolizone unit (rings B and C) (Figs. 1 and 2) [20]. Furthermore, the key HMBC correlations from H₂-12 to C-5/C-13, and from H-4 to C-6/C-13 demonstrated that above two units were fused via the C₅–C₁₃ bond (Fig. 2). Therefore, compound **1** with a rare 6/5/6 tricyclic ring system.

* Corresponding authors.

E-mail addresses: huzhxi88@163.com (Z.-X. Hu), haoxj@mail.kib.ac.cn (X.-J. Hao).

¹ These authors contributed equally to this work.





Fig. 1. Structures of compounds 1–5.

Fig. 2. The key HMBC, ^1H - ^1H COSY, and NOESY of 1–5.

The absolute configuration of **1** was further verified through electronic circular dichroism (ECD) calculations [21]. As a result, the calculated ECD spectrum of (6*R*)-**1** matched well with the experimental circular dichroism (CD) spectrum of **1** (Fig. 3). Therefore, the absolute configuration of the stereogenic center of **1** was assigned as 6*R*.

Sophortonkine B (**2**) was obtained as colorless oil. Its molecular formula, $\text{C}_{14}\text{H}_{22}\text{N}_2\text{O}_3$, was determined by the HRESIMS (m/z : 289.1539 [$\text{M} + \text{Na}$] $^+$, calcd. 289.1528). The ^1H NMR spectrum of **2**




Fig. 3. Experimental and calculated ECD spectra of 1–5.

showed the signals of two nitrogenated methines (δ_{H} 2.26, m, H-6; δ_{H} 4.20, d, $J = 10.6$ Hz, H-11) and two nitrogenated methenes (δ_{H} 2.72, m, H₂-2a; δ_{H} 2.28, m, H₂-2b; δ_{H} 2.74, m, H₂-10a; δ_{H} 2.25, m, H₂-10b). The ^{13}C and heteronuclear single quantum correlation spectroscopy (HSQC) spectra revealed 14 carbon signals due to one sp^2 quaternary carbon, two sp^3 quaternary carbons, two sp^3 methines, and nine sp^3 methylenes (Tables S1 and S2). The ^1H - ^1H COSY correlations of H₂-2/H₂-3/H₂-4 and H₂-8/H₂-9/H₂-10, together with the HMBC correlations of H-6 to C-2 (δ_{C} 52.4)/C-7 (δ_{C} 76.6)/C-10 (δ_{C} 53.8), of H₂-4 to C-5 (δ_{C} 92.1)/C-6 (δ_{C} 72.7), and of H₂-8 to C-7 displayed the presence of quinolizidine core (rings A and B) (Figs. 1 and 2) [22]. Meanwhile, the ^1H - ^1H COSY correlations of H-11/H₂-12/H₂-13/H₂-14, and the HMBC correlations of H-14 to C-15 (δ_{C} 173.7), of H-6 to C-7/C-11 (δ_{C} 64.6), and of H₂-12 to C-7 indicated the existence of hexahydro-5(1*H*)-indolizidone moiety (rings C and D) (Figs. 1 and 2) [23]. Moreover, the HMBC correlations of H-6 to C-11/C-7, of H-8 and H₂-12 to C-7, and of H₂-4 to C-5/C-6 indicated the above two moieties were connected *via* the C₅-C₆-C₇ bond. Thus, the unique 6/6/5/6 tetracyclic core have been formed on the basis of the fragments established above. Furthermore, the key HMBC correlations of 5-OH to C-5/C-6, and of 7-OH to C-7/C-8 demonstrated that two hydroxyl groups were connected to C-5 and C-7 respectively (Fig. 2).

The nuclear overhauser effect spectroscopy (NOESY) correlations of H-11/H₂-13b, H-11/H₂-8b, H₂-8b/H₂-9a, and H₂-9b/H-6 indicated that H-11 and H-6 were β - and α -oriented respectively. Meanwhile, the correlations of H₂-4b/H-11 and H₂-8b/H-11 revealed that C-5 and C-7 were all S^* . The absolute configuration of **2** was established as (5*S*, 6*R*, 7*S*, 11*R*) by the aforementioned evidence, the biosynthetic pathway, and X-ray diffraction analysis of biogenic homologue [20,23]. Moreover, the absolute configuration of **2** was further verified through ECD calculations (Fig. 3).

Sophortonkine C (**3**) was obtained as colorless oil. Its molecular formula was deduced to be $\text{C}_{19}\text{H}_{28}\text{N}_2\text{O}_2$, by HRESIMS (m/z 317.2220 [$\text{M} + \text{H}$] $^+$, calcd. 317.2224). The ^{13}C and HSQC spectroscopic data revealed the presence of total 19 carbon resonances, corresponding to two sp^2 quaternary carbons, two sp^3 quaternary carbons, two sp^3 methines, and thirteen sp^3 methylenes (Table S2). The aforementioned evidence suggested that compound **3** was an analogue of matrine [24]. The notable difference was that an

additional butan-2-one group (δ_C 30.8, 34.7, 37.0, 211.9) was fused between C-5 (δ_C 36.1) and C-6 (δ_C 62.6), which was supported by the ^1H - ^1H COSY correlation H_2 -18/ H_2 -19, and the obvious HMBC correlations between H_2 -18/ H_2 -19/ H_2 -21 and C-20 (δ_C 211.9), between H_2 -18 and C-4 (δ_C 28.7)/C-5/C-17 (δ_C 45.2), and between H_2 -21 and C-6/C-7 (Fig. 2). Thereby, compound **3** possessed an undescribed 6/6/6/6/6 pentacyclic skeleton.


The NOESY correlations of H-11/ H_2 -9a/ H_2 -8b, H-11/ H_2 -17b, H_2 -17b/ H_2 -3a, and H_2 -3a/ H_2 -4b revealed that these protons were β -oriented. Accordingly, the key NOESY correlations of H_2 -19a/ H_2 -4a/ H_2 -21a and H_2 -8a/H-7/ H_2 -18a revealed that C-5, C-6 and C-7 were $5R^*$, $6R^*$, $7R^*$ respectively (Fig. 2). Ultimately, the absolute configuration of **3** was identified as $5R$, $6R$, $7R$, $11R$ by ECD calculations (Fig. 3).

Sophoralopeine A (**4**) was obtained as colorless oil. Its molecular formula, $\text{C}_{16}\text{H}_{22}\text{N}_2\text{O}$, was determined by the HRESIMS (m/z : 259.1809 [$\text{M} + \text{H}$] $^+$, calcd. 259.1805). The ^1H NMR spectrum of **4** showed a set of AMX spin system of aromatic H atoms (δ_{H} 8.40, d, $J = 5.0$ Hz, H-14; δ_{H} 7.39, d, $J = 7.8$ Hz, H-16; δ_{H} 7.09, dd, $J = 7.8, 5.0$ Hz, H-15), a nitrogenated methine (δ_{H} 1.79, m, H-6), and two nitrogenated methenes (δ_{H} 3.91, dd, $J = 10.9, 5.6$ Hz, H_2 -11a; δ_{H} 3.79, dd, $J = 10.9, 2.0$ Hz, H_2 -11b; δ_{H} 3.15, d, $J = 11.8$ Hz, H_2 -2a; δ_{H} 1.72, m, H_2 -2b). The ^{13}C and HSQC spectra displayed resonances for two sp^2 quaternary carbons, three sp^2 methines, four sp^3 methines, and seven sp^3 methylenes (Tables S1 and S2). The ^1H - ^1H COSY correlations of H_2 -2/ H_2 -3/ H_2 -4/ H_2 -5/H-6/H-7/ H_2 -8/H-9/H-10/ H_2 -11, the HMBC correlations of H-2 to C-6 (δ_C 62.3), together with the chemical shift of C-2 (δ_C 53.5), C-6 (δ_C 62.3), and C-11 (δ_C 64.8) indicated the existence of decahydropyrido[1,2- α]azepine skeleton (rings A and B) (Figs. 1 and 2) [25]. Moreover, the ^1H - ^1H COSY correlations of H-14/H-15/H-16 and H_2 -18/H-7/ H_2 -8/H-9, together with the HMBC correlations of H-9 to C-12 (δ_C 162.3)/C-17 (δ_C 130.4), of H_2 -18a to C-16 (δ_C 138.1)/C-17/C-12, and of H-14 to C-12 indicated the existence of 5,6,7,8-tetrahydroquinoline moiety (rings C and D) (Figs. 1

and 2) [26]. Furthermore, the ^1H - ^1H COSY of H-7/ H_2 -8/H-9, and the HMBC correlation of H-10 to C-12 indicated the above two moieties were connected *via* the C₇-C₈-C₉ bond. Thus, the unique 6/7/6/6 tetracyclic core have been formed on the basis of the fragments established above.

The NOESY correlations of H_2 -18b/H-6 and H-6/H-10 indicated that these protons were cofacial and were arbitrarily assigned as β -oriented. Meanwhile, the correlations of H-7/ H_2 -18a, H_2 -18a/ H_2 -8b, H_2 -8b/H-9 revealed that H-7 and H-9 were all α -oriented (Fig. 2). Finally, the absolute configuration of **4** ($6R$, $7R$, $9S$, $10S$) was determined by ECD calculations (Fig. 3).

Sophoralopeine B (**5**) was obtained as colorless oil. Its molecular formula, $\text{C}_{17}\text{H}_{22}\text{N}_2\text{O}$, was determined by the HRESIMS (m/z : 271.1802 [$\text{M} + \text{H}$] $^+$, calcd. 271.1805). The ^1H NMR spectrum of **5** displayed two olefin protons (δ_{H} 5.81, d, $J = 6.1$ Hz, H-10; δ_{H} 5.67, d, $J = 6.1$ Hz, H-17), a nitrogenated methine (δ_{H} 4.94, d, $J = 3.1$ Hz, H-11), and two nitrogenated methenes (δ_{H} 3.69, ddd, $J = 17.1, 5.7, 4.3$ Hz, H_2 -2a; δ_{H} 3.57, ddd, $J = 17.1, 7.8, 4.3$ Hz, H_2 -2b; δ_{H} 3.43, dd, $J = 14.1, 6.9$ Hz, H_2 -13a; δ_{H} 2.90, m, H_2 -13b). The ^{13}C and HSQC spectra displayed resonances for one methyl, seven sp^3 methylenes, two sp^2 methines, three sp^3 methines, and four sp^2 quaternary carbons (Tables S1 and S2). The ^1H - ^1H COSY correlations of H_2 -2/ H_2 -3/ H_2 -4, and H-7/ H_2 -8/H-9/H-10, combined with the HMBC correlations of H-2, H-7, and H_2 -8 to C-6 (δ_C 167.1), and of H_2 -4 to C-5 (δ_C 128.8)/C-6/C-10 (δ_C 132.5) indicated the existence of 2,3,4,6,7,8-hexahydroquinoline skeleton (rings A and B) (Figs. 1 and 2) [27]. Meanwhile, the ^1H - ^1H COSY correlations of H-17/H-7/ H_2 -8/H-9/H-11 and H_2 -13/ H_2 -14/ H_2 -15, together with the HMBC correlations of H-11 to C-13 (δ_C 42.9)/C-16 (δ_C 134.4)/C-17 (δ_C 125.7), of H-17 to C-15 (δ_C 27.3) indicated the existence of octahydroquinoline moiety (rings C and D) (Figs. 1 and 2) [28]. Furthermore, the ^1H - ^1H COSY H-17/H-7/ H_2 -8/H-9/H-10 indicated the above two moieties were connected *via* the C₇-C₈-C₉ bond. Thus, the unique 6/6/6/6 tetracyclic core have been formed on the basis of the fragments established above. In addition, the key HMBC cor-



Scheme 1. Hypothetical biosynthetic pathways for **1-5**.

relations of H₂-13 to the acetyl group (δ_C 169.8) demonstrated that the acetoxy group was connected to N-12 (Fig. 2).

The NOESY correlations of H₂-15b/H-11, H-11/H₂-8b, and H-9/H₂-8b/H-7 indicated that H-7, H-9, and H-11 were α -oriented (Fig. 2). Finally, the absolute configuration of **5** (7*R*, 9*R*, 11*S*) was determined by ECD calculations (Fig. 3).

The biosynthetic pathway for **1–5** are illustrated in Scheme 1. L-Lysine undergoes a series of reactions to yield matrine and aloperine [6,7]. Matrine could be converted to 5,6-dehydro-matrine through oxidation and dehydration, followed by oxidative ring-opening and intramolecular nucleophilic addition to generate the key intermediate alopecuroidine A [20]. On the one hand, alopecuroidine A undergoes ring-opening, C–N bond cleavage, electromigration, and oxidative reaction to generate **1** [29]. On the other hand, alopecuroidine A goes through ring-opening, Michael addition reaction, decarboxylation, and oxidation to yield **2** [30]. Moreover, 5,6-dehydro-matrine undergoes the Michael addition with acetoacetyl-CoA to obtained **B1**. After cyclization and reduc-

tion, **B1** could afford **3** [30]. The key intermediate **C2** was derived from aloperine through reduction and oxidative ring-opening [30]. Subsequently, **C2** could further generate **4** via *S*-adenosyl methionine (SAM) catalysed methylation, Michael addition, and reduction [31–33]. In addition, **C2** undergoes a cascade of reduction, Michael addition, dehydration, and acetylation to obtain **5** [34].

The anti-TMV activities of **1–5** were evaluated using the half-leaf method (100 mg/L) (Table S3 in Supporting information) [2]. Notably, **5** displayed a significant protective effect and curative effect with concentration for 50% of maximal effect (EC₅₀) values of 19.6 μ g/mL (curative), which was superior to that of positive control ningnanmycin (EC₅₀: 54.8 μ g/mL) (Table S4 in Supporting information). Moreover, the transcription levels of the TMV *Cp* and *RdRp* genes were detected by quantitative real time polymerase chain reaction (qRT-PCR) in the inoculated and systematic leaves for the *in vivo* curative and protective assays. Biological tests indicated that compound **5** strongly inhibited the expression of the TMV *Cp* and *RdRp* genes (Fig. 4).




Fig. 4. The expression levels of TMV *Cp* and *RdRp* genes in inoculated and systematic K₃₂₆ leaves following treatment with **5** in protective and curative effects. (A) The level of TMV *Cp* gene expression in inoculated leaves (protective). (B) The level of TMV *Cp* gene expression in systematic leaves (protective). (C) The level of TMV *Cp* gene expression in inoculated leaves (curative). (D) The level of TMV *Cp* gene expression in systematic leaves (curative). (E) The level of TMV *RdRp* gene expression in inoculated leaves (protective). (F) The level of TMV *RdRp* gene expression in systematic leaves (protective). (G) The level of TMV *RdRp* gene expression in inoculated leaves (curative). (H) The level of TMV *RdRp* gene expression in systematic leaves (curative). Solution of equal DMSO was used as a negative control agent (CK).

In summary, this study established the structures of five new QAs covering five novel skeletons. Bioactivity evaluations revealed that **5** displayed significant anti-TMV activity than the positive control ningnanmycin. Furthermore, compound **5** could not only inhibit the accumulation of TMV *Cp* and *Rdrp* genes but also enhance the host plant's resistance to TMV infection. Therefore, compound **5** can serve as a lead compound for the discovery of new antiviral agents for the management of TMV.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The work was financially supported by the National Natural Science Foundation of China (Nos. 32160103 and U1812403), the Science and Technology Department of Guizhou Province (Nos. QKH ZC-[2021]-YB181, QKH CXTD-[2022]-007 and QKH ZYD-[2022]-4015), and Guizhou Provincial Engineering Research Center for Natural Drugs.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ccllet.2023.108927.

References

- [1] K. Saito, Y. Koike, H. Suzuki, et al., *Phytochemistry* 34 (1993) 1041–1044.
- [2] J.B. Zou, L.H. Zhao, P. Yi, et al., *J. Agric. Food Chem.* 68 (2020) 15015–15026.
- [3] Y.B. Zhang, D. Luo, L. Yang, et al., *J. Nat. Prod.* 81 (2018) 2259–2265.
- [4] X. Yuan, J. Jiang, Y. Yang, et al., *Chin. Chem. Lett.* 33 (2022) 2923–2927.
- [5] P. Zhang, J. Zhang, Q. An, et al., *J. Agric. Food Chem.* 71 (2023) 4394–4407.
- [6] J. Rouden, M.C. Lasne, J. Blanchet, et al., *Chem. Rev.* 114 (2014) 712–778.
- [7] A. Salatino, O.R. Gottlieb, *Biochem. Syst. Ecol.* 8 (1980) 133–147.
- [8] S. Bunsupa, M. Yamazaki, K. Saito, *Front. Plant Sci.* 3 (2012) 239.
- [9] S.K. Chellappan, Y.X. Xiao, W. Tueckmantel, et al., *J. Med. Chem.* 49 (2006) 2673–2676.
- [10] K.S. Zhou, P. Yi, T. Yang, et al., *J. Org. Lett.* 21 (2019) 5051–5054.
- [11] B.C. Zhang, Z.Q. Sun, M. Lv, et al., *J. Agric. Food Chem.* 66 (2018) 12898–12910.
- [12] S. Tang, L.Y. Kong, Y.H. Li, et al., *ACS Med. Chem. Lett.* 6 (2015) 183–186.
- [13] H. Xu, M. Xu, Z.Q. Sun, et al., *J. Agric. Food Chem.* 67 (2019) 12182–12190.
- [14] A.E. Blom, H.R. Campello, H.A. Lester, et al., *J. Am. Chem. Soc.* 141 (2019) 15840–15849.
- [15] S. Tang, Z.G. Peng, X. Zhang, et al., *Chin. Chem. Lett.* 27 (2016) 1052–1057.
- [16] H. Wang, D. Yang, W. Zhang, et al., *Chin. Chem. Lett.* 34 (2023) 107258.
- [17] M. Xu, C. Ren, Y. Zhou, et al., *Chin. Chem. Lett.* 34 (2023) 107585.
- [18] Z.X. Hu, P. Zhang, J.B. Zou, et al., *J. Org. Chem.* 87 (2022) 11309–11318.
- [19] Z.X. Hu, P. Zhang, J.B. Zou, et al., *J. Agric. Food Chem.* 70 (2022) 9214–9226.
- [20] X. Yuan, Z. Li, Z. Feng, et al., *Chin. Chem. Lett.* 32 (2021) 4058–4062.
- [21] G. Bringmann, T. Bruhn, K. Maksimenka, et al., *Eur. J. Org. Chem.* 17 (2009) 2717–2727.
- [22] D. Luo, N.H. Chen, W.Z. Wang, et al., *Chin. J. Chem.* 39 (2021) 3339–3346.
- [23] D. Luo, Z.N. Wu, J.H. Zhang, et al., *Chin. J. Chem.* 39 (2021) 2555–2562.
- [24] Y.Y. Zhao, Q.Y. Pang, J.B. Liu, et al., *Nat. Prod. Res. Dev.* 6 (1994) 10–13.
- [25] L.Y. Xi, R.Y. Zhang, S. Liang, et al., *Org. Lett.* 16 (2014) 5269–5271.
- [26] L. Cui, L.W. Ye, L.M. Zhang, *Chem. Commun.* 46 (2010) 3351–3353.
- [27] E. Schuster, G. Jas, D. Schumann, *Org. Prep. Proced. Int.* 24 (1992) 670–672.
- [28] J.E.M.N. Klein, H. Muller-Bunz, P. Evans, *Org. Biomol. Chem.* 7 (2009) 986–995.
- [29] Y.B. Zhang, L. Yang, D. Luo, et al., *Org. Lett.* 20 (2018) 5942–5946.
- [30] Y.B. Zhang, X.L. Zhang, N.H. Chen, et al., *Org. Lett.* 19 (2017) 424–427.
- [31] B.J. Zhang, M.F. Bao, C.X. Zeng, et al., *Org. Lett.* 16 (2014) 6400–6403.
- [32] J.J. Xue, C.Y. Jiang, D.L. Zou, et al., *Org. Lett.* 22 (2020) 7439–7442.
- [33] P. Dewick, *Medicinal Natural Products, A Biosynthetic Approach*, 2nd ed., Wiley, Nottingham, 2009.
- [34] J.X. Wang, Y.P. Zhao, N.N. Du, et al., *Org. Lett.* 22 (2020) 8240–8244.